Formycon Launches Epruvy (Biosimilar, Lucentis) in the Germany

Shots: 

• Sandoz commercializes Epruvy (Biosimilar, Lucentis) across Germany in PFS and vial forms, following an agreement with Formycon and Bioeq  

• Epruvy (ranibizumab)was approved by the EMA in Sep’24 to treat severe visual impairments like nAMD and other retinopathies and is marketed by Sandoz in Germany under a Bioeq license  

• Epruvy is available in vials and pre-filled syringes, offering a convenient treatment option in Germany 

Ref: Formycon | Image: Formycon  | Press Release

Related News:- Formycon and Klinge Biopharma sign a semi-exclusive licensing deal with Horus Pharma to commercialize the FYB203/Baiama (Biosimilar, Eylea)  

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com